TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23207855

Group type: EXPERIMENTAL
Intervention: Memory chain (MC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Super slick chain (SSC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Plastic chain (PC)
Number of subjects: 13
Study: 20185164

Group type: EXPERIMENTAL
Intervention: Prostacyclin analogue (PGI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 23
Study: 16199835

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 533

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 533

Group type: COMPARATOR
Intervention: Risperidone vs Haloperidol
Number of subjects: 533
Study: 12874742

Group type: EXPERIMENTAL
Intervention: Oral kilocalorie and protein supplementation for 3 months (treatment group)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No intervention (low-risk group)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral kilocalorie and protein supplementation (treatment group)
Number of subjects: 117
Study: 10776134

Group type: EXPERIMENTAL
Intervention: Teaching Method 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teaching Method 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teaching Method 3
Number of subjects: 0
Study: 8539676

Group type: EXPERIMENTAL
Intervention: Patients with limb girdle dystrophy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (age-matched normal group)
Number of subjects: 15
Study: 2146231

Group type: EXPERIMENTAL
Intervention: Trospectomycin 250 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trospectomycin 500 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trospectomycin 750 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 30
Study: 589769

Group type: EXPERIMENTAL
Intervention: D. pteronyssinus extract
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31931884

Group type: EXPERIMENTAL
Intervention: LINC‐II intervention (strengths‐based HIV case management, rapid ART initiation, pharmacotherapy for opioid use disorder)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: LINC‐II intervention
Number of subjects: 240
Study: 30797396

Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention (CBI)
Number of subjects: 237
Study: 27865630

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg + Nimesulide 100mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone + Placebo
Number of subjects: 40
Study: 25216791

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 51
Study: 23454066

Group type: EXPERIMENTAL
Intervention: High-fidelity patient simulator
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Static mannequin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Paper/pencil case study
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 86
Study: 21672252

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination-Young (GSD-Y) intervention during 8 outpatient visits
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination-Young (GSD-Y) intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group receiving standard visits
Number of subjects: 68
Study: 19148448

Group type: EXPERIMENTAL
Intervention: Apicectomy and root canal obturation completed one time under direct vision (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Apicectomy done after RCT (Group B)
Number of subjects: 34
Study: 15921866

Group type: EXPERIMENTAL
Intervention: Candesartan (16 mg/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Felodipine (5 mg/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Basal FBF
Number of subjects: 29
Study: 12576119

Group type: EXPERIMENTAL
Intervention: Deprived conditions
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fed conditions
Number of subjects: 17
Study: 10832765

Group type: EXPERIMENTAL
Intervention: Phentermine (PHE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sibutramine (SIB)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9110007

Group type: EXPERIMENTAL
Intervention: IV ketorolac (1 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 34
Study: 8268432

Group type: EXPERIMENTAL
Intervention: Disconnection of the ventilatory system
Number of subjects: 712

Group type: COMPARATOR
Intervention: Continuation of the ventilatory system
Number of subjects: 712

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure
Number of subjects: 712

Group type: COMPARATOR
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 712

Group type: COMPARATOR
Intervention: Surgeon-related risk factor
Number of subjects: 712
Study: 3543161

Group type: EXPERIMENTAL
Intervention: Acedapsone (3 injections at 10 weeks interval)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (3 injections at 10 weeks interval)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Acedapsone
Number of subjects: 560
Study: 29362929

Group type: EXPERIMENTAL
Intervention: Multimodal ADHD treatment (group psychotherapy plus methylphenidate)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Parent-child training (PCT) program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Clinical management (mainly supportive counselling)
Number of subjects: 125
Study: 25860822

Group type: EXPERIMENTAL
Intervention: Mental Practice (MP) for 20 minutes
Number of subjects: 78

Group type: COMPARATOR
Intervention: Advanced Trauma Life Support (ATLS) training for 20 minutes
Number of subjects: 78
Study: 25523036

Group type: EXPERIMENTAL
Intervention: ORAL IMPACT® (preoperative oral immunonutrition)
Number of subjects: 400

Group type: COMPARATOR
Intervention: IMPACT CONTROL® (isocaloric isonitrogenous supplement)
Number of subjects: 400
Study: 21880080

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate (SPS)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Lactulose (L)
Number of subjects: 348
Study: 20075788

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 212
Study: 18296130

Group type: EXPERIMENTAL
Intervention: Intensive granulocyte and monocyte adsorption (GMA) with Adacolumn, 2 sessions/week for 3 weeks, then 1 session/week for up to 11 sessions (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous prednisolone, 40-60 mg/day for 5-10 days (n = 35)
Number of subjects: 70
Study: 16158009

Group type: EXPERIMENTAL
Intervention: DemTect cutoff score of ≤11 points for DAT
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DemTect cutoff score of ≤13 points for MCI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DemTect cutoff score of ≤13 points for AD-typical patterns of cerebral glucose metabolism
Number of subjects: 38
Study: 11843742

Group type: EXPERIMENTAL
Intervention: Intranasal PCA diamorphine (1.0 mg bolus, 3 min lockout)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous PCA diamorphine (0.5 mg bolus, 3 min lockout)
Number of subjects: 52
Study: 10399792

Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients with sicca symptoms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sarcoidosis patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sjögren's syndrome patients
Number of subjects: 12
Study: 7742578

Group type: EXPERIMENTAL
Intervention: Cyclosporin alone (CsA group, n = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Azathioprine-prednisone (AzP group, n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both CsA and AzP groups combined
Number of subjects: 22
Study: 2258784

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study: 6270978

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy
Number of subjects: 387

Group type: COMPARATOR
Intervention: No bone scintigraphy
Number of subjects: 387
Study: 30621718

Group type: EXPERIMENTAL
Intervention: Individualised multidisciplinary intervention (n=59)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard management (n=60)
Number of subjects: 119
Study: 29667211

Group type: EXPERIMENTAL
Intervention: Celecoxib 100-200 mg b.d.
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Ibuprofen 600-800 mg t.d.s.
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Naproxen 375-500 mg b.d.
Number of subjects: 24081
Study: 27440562

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 32

Group type: COMPARATOR
Intervention: Anterior approach
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anatomic reinsertion of the ruptured tendon
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Limited supinator muscle fat content
Number of subjects: 32
Study: 24251955

Group type: EXPERIMENTAL
Intervention: Mother's scent
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Flexion position
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 21718964

Group type: EXPERIMENTAL
Intervention: Pressure-relief mattress
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional mattress
Number of subjects: 12
Study: 20716305

Group type: EXPERIMENTAL
Intervention: 300 mg per week of oral naltrexone plus standard psychosocial treatment as usual (n = 56)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard psychosocial treatment as usual (TAU) without naltrexone (n = 55)
Number of subjects: 111
Study: 17563698

Group type: EXPERIMENTAL
Intervention: Robot-assisted total knee arthroplasty
Number of subjects: 25
Study: 16779027

Group type: EXPERIMENTAL
Intervention: IT evaluation studies
Number of subjects: 64

Group type: COMPARATOR
Intervention: Randomized controlled trials (RCT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Multi-centre studies
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Quality of evaluation studies
Number of subjects: 64
Study: 12021498

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal CRM 197 conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive immunoprophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mucosal immunization and DNA/gene technology
Number of subjects: 0
Study: 9042984

Group type: EXPERIMENTAL
Intervention: Famotidine 10 mg
Number of subjects: 366

Group type: COMPARATOR
Intervention: Alginate (2 x 250 mg chewable tablets)
Number of subjects: 366
Study: 7836717

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (four doses)
Number of subjects: 68
Study: 2856596

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate
Number of subjects: 265

Group type: COMPARATOR
Intervention: Enteric‐coated erythromycin
Number of subjects: 265
Study: 29550020

Group type: EXPERIMENTAL
Intervention: Topical dipyrone gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 120
Study: 27056738

Group type: EXPERIMENTAL
Intervention: ABC-bleeding score (age, biomarkers [GDF-15, cTnT-hs, haemoglobin], clinical history [previous bleeding])
Number of subjects: 22505

Group type: EXPERIMENTAL
Intervention: Modified ABC-bleeding score using alternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance)
Number of subjects: 22505
Study: 24771090

Group type: EXPERIMENTAL
Intervention: Basal insulin glargine
Number of subjects: 12537

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study: 22858703

Group type: EXPERIMENTAL
Intervention: Self-etch bond (SeB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single Bond (SB)
Number of subjects: 35
Study: 20158586

Group type: EXPERIMENTAL
Intervention: sulfasalazine (maximum 2.5 g/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: sulfasalazine
Number of subjects: 52
Study: 18375786

Group type: EXPERIMENTAL
Intervention: Sectioning of the conoid ligament
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sectioning of the trapezoid ligament
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Complete acromioclavicular joint injury with partial disruption of the coracoclavicular ligament complex
Number of subjects: 40
Study: 17012867

Group type: EXPERIMENTAL
Intervention: Yellow fever 17D vaccine
Number of subjects: 43532
Study: 15107935

Group type: EXPERIMENTAL
Intervention: VACOP-B for 6 weeks plus involved field radiotherapy (Stage I)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: VACOP-B for 12 weeks plus involved field radiotherapy on residual masses (Stage II)
Number of subjects: 93
Study: 11783327

Group type: EXPERIMENTAL
Intervention: HANS plus small dose of buprenorphine (BPN)
Number of subjects: 33

Group type: COMPARATOR
Intervention: BPN
Number of subjects: 33
Study: 9595795

Group type: EXPERIMENTAL
Intervention: Oxygen administration by nasal cannula during the first or second postoperative night
Number of subjects: 15

Group type: COMPARATOR
Intervention: No oxygen therapy (control group)
Number of subjects: 15
Study: 8357297

Group type: EXPERIMENTAL
Intervention: Alprazolam (titrated upward to reach 6.0 mg/d)
Number of subjects: 237
Study: 2877953

Group type: EXPERIMENTAL
Intervention: 10 mg per day dihydroergotamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3142203

Group type: EXPERIMENTAL
Intervention: Strapping with an inelastic tape
Number of subjects: 200

Group type: COMPARATOR
Intervention: Operation and a walking cast
Number of subjects: 200

Group type: COMPARATOR
Intervention: Walking cast alone
Number of subjects: 200
Study: 31410765

Group type: EXPERIMENTAL
Intervention: Lozenges containing Lactobacillus reuteri taken twice daily for 90 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 31005243

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 399

Group type: COMPARATOR
Intervention: PORT
Number of subjects: 399
Study: 28177568

Group type: EXPERIMENTAL
Intervention: Listening to parents' recorded voice during sedation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not listening to parents' recorded voice during sedation
Number of subjects: 50
Study: 26048186

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23481576

Group type: COMPARATOR
Intervention: Colposcopy only
Number of subjects: 751

Group type: COMPARATOR
Intervention: Colposcopy with biopsy
Number of subjects: 751

Group type: COMPARATOR
Intervention: Colposcopy with LLETZ
Number of subjects: 751
Study: 21451152

Group type: EXPERIMENTAL
Intervention: EZG(RTG) 1,200 mg/day
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 18713759

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078

Group type: COMPARATOR
Intervention: Major bleeding
Number of subjects: 20078
Study: 16708359

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Positive mood
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 57
Study: 15301297

Group type: EXPERIMENTAL
Intervention: Specific IgE levels in serum
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral food challenges (cow milk, hen egg, wheat)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 74
Study: 11810123

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP) at 0 cmH2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP) at 8 cmH2O
Number of subjects: 10
Study: 8996417

Group type: EXPERIMENTAL
Intervention: USA treatment
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Other countries treatment
Number of subjects: 2972
Study: 8491245

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg (Group 1, n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg (Group 2, n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and doxazosin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg (Group 2) with addition of Nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Doxazosin 2 mg (Group 2)
Number of subjects: 12
Study: 3695671

Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional medical clinic
Number of subjects: 50
Study: 30166303

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 26755229

Group type: EXPERIMENTAL
Intervention: Colloid preload with 0.5 L of 6% w/v hydroxyethyl starch solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prophylactic IV infusion of 15 mg ephedrine
Number of subjects: 60
Study: 25401512

Group type: EXPERIMENTAL
Intervention: IOL-shell technique (Group II)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional phacoemulsification (Group I)
Number of subjects: 80
Study: 23347711

Group type: EXPERIMENTAL
Intervention: Information and counseling provision using the 'patient journey' model
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 158
Study: 20880872

Group type: EXPERIMENTAL
Intervention: TLC-CPAP (n=124)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention placebo control (n=126)
Number of subjects: 250
Study: 18358724

Group type: EXPERIMENTAL
Intervention: Virtual reality‐based treadmill training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill training (control)
Number of subjects: 20
Study: 16641468

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (Boost Plus)
Number of subjects: 0
Study: 14716631

Group type: EXPERIMENTAL
Intervention: Individualized optimum adaptation pattern derived for each patient
Number of subjects: 0
Study: 10026369

Group type: EXPERIMENTAL
Intervention: Continuous 6-ppm dose of inhaled nitric oxide (iNO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 20 ppm iNO for 4 h followed by 6 ppm
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Either treatment
Number of subjects: 29
Study: 8677926

Group type: EXPERIMENTAL
Intervention: Drug treatment for functional dyspepsia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1912715

Group type: EXPERIMENTAL
Intervention: Combination of senna pods and Goleytely solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Goleytely solution (7 litres)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Simethicone (additional administration)
Number of subjects: 80
Study: 6761136

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30300800

Group type: EXPERIMENTAL
Intervention: Oral naltrexone treatment for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dropped out of naltrexone treatment
Number of subjects: 120
Study: 27150606

Group type: EXPERIMENTAL
Intervention: Usual clinical practice augmented by decision aid websites
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual clinical practice alone
Number of subjects: 48
Study: 24801451

Group type: EXPERIMENTAL
Intervention: 10-point scale
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 7-point scale
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 4-point scale
Number of subjects: 82
Study: 21810843

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: Combination therapy (statins, antithrombotics, ACEI/ARB)
Number of subjects: 2270
Study: 20623976

Group type: EXPERIMENTAL
Intervention: Early enteral probe feeding (EEPF) conduction
Number of subjects: 32
Study: 18813830

Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel (Arm A): Cisplatin 80 mg/m² and paclitaxel 175 mg/m² on day 1, repeated every 3 weeks.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cisplatin-etoposide (Arm B): Cisplatin 80 mg/m² on day 1 and etoposide 120 mg/m² per day on days 1-3, repeated every 3 weeks.
Number of subjects: 108
Study: 15741845

Group type: EXPERIMENTAL
Intervention: Electrostimulation training (EMS) - 30 contractions (4‐s duration, 85 Hz), 3 times a week for 3 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Electrostimulation training (EMS)
Number of subjects: 17
Study: 15493240

Group type: EXPERIMENTAL
Intervention: Graphic Organizers (GOs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Graphic Organizers (No GO)
Number of subjects: 0
Study: 10460524

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol, sufentanil and atracurium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group 1)
Number of subjects: 40
Study: 7876922

Group type: EXPERIMENTAL
Intervention: Lauric acid diet (4% of energy from lauric acid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Palmitic acid diet (4% of energy from palmitic acid)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline diet (4% of energy from monoenes)
Number of subjects: 15
Study: 2797847

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ranitidine 150 mg B.I.D
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 18